DEF 14A

Company

Kalaris Therapeutics, Inc.

Filed

July 1, 2025

Period of Report

August 12, 2025

Accession Number

0001193125-25-153439

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →